Octapharma AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Octapharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3434
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Octapharma AG (Octapharma) is a human protein manufacturer that focuses on developing and producing human proteins from human plasma and cell lines. The company treats patients worldwide with products across immunotherapy (immune disorders), haematology (coagulation disorders), and critical care therapeutic areas. It sources majority of plasma from company-owned donation centers. Octapharma owns plasma donation centers in the USA and in Germany, and owns six state-of-the-art production facilities in Austria, Germany, France, Mexico and Sweden. The company’s production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labelling, packaging, storage and distribution. Octapharma is headquartered in Lachen, Switzerland.

Octapharma AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Octapharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Octapharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Octapharma AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Octapharma Enters Into Co-Marketing Agreement With Pfizer 10
Licensing Agreements 11
Hikma Pharma Enters into Licensing Agreement with Octapharma 11
Octapharma Enters into Licensing Agreement with Glycotope 12
Equity Offering 13
Glycotope to Raise USD90 Million in Private Placement of Shares 13
Octapharma AG – Key Competitors 14
Octapharma AG – Key Employees 15
Octapharma AG – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 19
Financial Announcements 19
Mar 01, 2018: Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million 19
Mar 01, 2017: Octapharma Group Publishes 2016 Annual Results Reporting Revenue of €1.6 Billion and Operating Income of €383 Million 20
Product News 21
May 28, 2018: Octapharma present new data on the benefits of Nuwiq in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress 21
Clinical Trials 22
May 28, 2018: Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Octapharma AG, Pharmaceuticals & Healthcare, Key Facts 2
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Octapharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Octapharma AG, Deals By Therapy Area, 2012 to YTD 2018 8
Octapharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Octapharma Enters Into Co-Marketing Agreement With Pfizer 10
Hikma Pharma Enters into Licensing Agreement with Octapharma 11
Octapharma Enters into Licensing Agreement with Glycotope 12
Glycotope to Raise USD90 Million in Private Placement of Shares 13
Octapharma AG, Key Competitors 14
Octapharma AG, Key Employees 15
Octapharma AG, Other Locations 16
Octapharma AG, Subsidiaries 16

List of Figures
Octapharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Octapharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Octapharma AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cardiva Medical Inc:企業の戦略的SWOT分析
    Cardiva Medical Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Faisal Islamic Bank of Egypt (SAE) (FAITA):企業の財務・戦略的SWOT分析
    Faisal Islamic Bank of Egypt (SAE) (FAITA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Regeneron Pharmaceuticals Inc (REGN)-製薬・医療分野:企業M&A・提携分析
    Summary Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company provides products for treating eye diseases, high low-density lipoprotein (LDL) choleste …
  • NV Bekaert SA:企業のM&A・事業提携・投資動向
    NV Bekaert SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NV Bekaert SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Eesti Energia AS:戦略・SWOT・企業財務分析
    Eesti Energia AS - Strategy, SWOT and Corporate Finance Report Summary Eesti Energia AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Hampshire Trust Bank Plc:企業の戦略・SWOT・財務情報
    Hampshire Trust Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Hampshire Trust Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Zara Investment (Holding) Co Ltd:企業の戦略・SWOT・財務分析
    Zara Investment (Holding) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Zara Investment (Holding) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sound Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Sound Pharmaceuticals Inc (SPI) is a biopharmaceutical company that develops therapeutics for sensorineural otologic diseases. The company's product pipeline includes SPI-1005, SPI-3005 and SPI-5557. Its SPI-1005 is a proprietary oral formulation of ebselen, a small molecule mimic and induce …
  • United BioSource Corp-製薬・医療分野:企業M&A・提携分析
    Summary United BioSource Corp (UBC), a subsidiary of Express Scripts Holding Company is a provider of pharmaceutical support services. The company offers medicines and medical products. Its services comprise clinical development and late stage research, risk management and pharmacovigilance, nursing …
  • Life Healthcare Group Holdings Ltd (LHC):企業の財務・戦略的SWOT分析
    Life Healthcare Group Holdings Ltd (LHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • 2020 GeneSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary 20/20 GeneSystems Inc (20/20 Gene) is a medical diagnostic company. The company discovers, develops, and commercializes proteomics products and diagnostic tests for therapy selection, early disease detection, and biodefense applications. It provides tests in the areas of early detection of l …
  • Advanced Energy Industries, Inc. (AEIS)-エネルギー分野:企業M&A・提携分析
    Summary Advanced Energy Industries, Inc. (Advanced Energy) is a provider of power conversion, measurement and control solutions. The company designs, manufactures, sells, and supports power conversion products and solutions. These products are used in various applications ranging from manufacturing …
  • Grande Asset Hotels And Property Pcl:企業の戦略・SWOT・財務分析
    Grande Asset Hotels And Property Pcl - Strategy, SWOT and Corporate Finance Report Summary Grande Asset Hotels And Property Pcl - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Mitsubishi Estate Co., Ltd. (8802):企業の財務・戦略的SWOT分析
    Mitsubishi Estate Co., Ltd. (8802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Disproquima S.A.:戦略・SWOT・企業財務分析
    Disproquima S.A. - Strategy, SWOT and Corporate Finance Report Summary Disproquima S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Euro Disney S.C.A.:戦略・SWOT・企業財務分析
    Euro Disney S.C.A. - Strategy, SWOT and Corporate Finance Report Summary Euro Disney S.C.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Medtecs International Corp Ltd (546):企業の財務・戦略的SWOT分析
    Summary Medtecs International Corporation Ltd (Medtecs) is a medical device company that manufactures and distributes work wear apparels and medical device and consumables. The company's products include medical devices, healthcare textile work wear and hospitality textiles, among others. It also pr …
  • Big Rivers Electric Corp:企業の戦略的SWOT分析
    Big Rivers Electric Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • PendoPharm Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PendoPharm Inc (PendoPharm), a subsidiary of Pharmascience Inc, is a healthcare company that provides production and commercialization of a wide range of drugs. The company provides products such as spans prescription drugs, over-the-counter and behind-the-counter products, among others. Its …
  • Lego AS:企業の戦略的SWOT分析
    Lego AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆